AlloVir

📍 Waltham, United States👥 129 employees💰 Last funded Mar 2022
Biotechnology Research🌐 allovir.com
Website LinkedIn
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2019–2022 · investors recorded per year
2019220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in AlloVir?
AlloVir has 3 investors on record on gritt.io.
When did AlloVir last raise funding?
The most recent investment in AlloVir recorded on gritt.io was in March 2022.
What industry is AlloVir in?
AlloVir operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AlloVir based?
AlloVir is headquartered in Waltham, United States.